Fully Human Antibodies for Malignant Pleural Mesothelioma Targeting.

ABSTRACT: Immunotherapy is the most promising therapeutic approach against malignant pleural mesothelioma (MPM). Despite technological progress, the number of targetable antigens or specific antibodies is limited, thus hindering the full potential of recent therapeutic interventions. All possibilities of finding new targeting molecules must be exploited. The specificity of targeting is guaranteed by the use of monoclonal antibodies, while fully human antibodies are preferred, as they are functional and generate no neutralizing antibodies. The aim of this review is to appraise the latest advances in screening methods dedicated to the identification and harnessing of fully human antibodies. The scope of identifying useful molecules proceeds along two avenues, i.e., through the antigen-first or binding

SUBMITTER: Nicolini F 

PROVIDER: S-EPMC7226231 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature